Study type

Study topic

Disease /health condition
Human medicinal product

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

METHOTREXATE
Population studied

Short description of the study population

Women on MTX (≤30mg/week) either in the post-conception period or within 12 weeks before conception.

Age groups

Preterm newborn infants (0 – 27 days)
Term newborn infants (0 – 27 days)
Infants and toddlers (28 days – 23 months)
Adults (18 to < 46 years)
Adults (46 to < 65 years)

Special population of interest

Pregnant women

Estimated number of subjects

1450
Study design details

Main study objective

To assess the risk of low-dose methotrexate (MTX) exposure in early pregnancy.

Outcomes

Rate of major birth defects, rate of specific MTX embryopathy, rate of spontaneous abortion, rate of elective terminations of pregnancies, birth weight, rate of prematurity, Definition of a "teratogenic time window", Evaluation of teratogenic dose-effect relationship.

Data analysis plan

Birth defect rates include live births and anomalies in elective terminationsof pregnancies (ETOPs) and miscarriages. For calculating rates ofmajor birth defects possibly associated with a teratogen, welldefinedgenetic syndromes are excluded. See: Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol. 2008,26:36-41. For calculation spontaneous abortion rate see Meister R, Schaefer C. Statistical methods for estimating the probability ofspontaneous abortion in observational studies--analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol. 2008,26:31-5
Documents